Table 1.

Repartition of FQ-resistant VGS among oropharyngeal samples

Parameter measuredSource
Hospitalized patientsHealthy controlsTotal
FQ treatedaNon-FQ treated
No. of samplesb 30303090
No. of samples with FQ-resistant VGSc 98320
  • a Patients were treated for infections other than those of the upper respiratory tract.

  • b One oropharyngeal sample per patient or healthy control.

  • c Analysis by χ2 test comparing the number of samples containing FQ-resistant VGS (for which ciprofloxacin MICs were ≥4 μg/ml) from hospitalized patients and healthy controls showed a statistical difference (P = 0.0486).